Net Clinical Benefit of Ticagrelor Compared to Clopidogrel in patients with Acute Coronary Syndrome

*Co-corresponding authors: Rae Woong Park, MD, PhD 1, Harlan M. Krumholz, MD 2

1 Department of Biomedical Informatics, Ajou University School of Medicine; 2 Yale University School of Medicine

Collaborators: Seng Chan You1; Yeunsook Rho2; Jiwoo Kim2; Anastasios Siapos3; Ajit Londhe4; Jaehyeong Cho5; Jimyung Park5; Martijn Schuemie4; Marc A Suchard, MD, PhD6,7; David Madigan PhD8; George Hripcsak MD9; Christian G. Reich3; Patrick B. Ryan4; Rae Woong Park, MD, PhD1,5; Harlan M. Krumholz, MD10

1Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea; 2Health Insurance Review and Assessment Service, Wonju, Korea; 3Real World Evidence Solutions, IQVIA, Durham, NC, USA; 4Janssen Research and Development, Titusville, USA; 5Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea; 6Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA; 7Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA; 8Department of Statistics, Columbia University, New York, NY, USA; 9Medical Informatics Services, New York-Presbyterian Hospital, New York, NY, USA; 10Department of Medicine, Yale University School of Medicine, New Haven, CA, USA


The authors declare the following disclosures: Mr. Londhe, Dr. Schuemie, and Dr. Ryan are employees of Janssen Research & Development, a subsidiary of Johnson & Johnson. Dr. Reich and Mr. Siapos are employees of IQVIA. Neither Janssen nor IQVIA had input in the design, execution, interpretation of results or decision to publish.